7Baggers

We provide you with 20 years of free, institutional-grade data for AVDL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVDL. Explore the full financial landscape of AVDL stock.

Reported DateCIKTickerType
2024-02-291012477AVDL10-KUrl
2023-11-081012477AVDL10-QUrl
2023-08-091012477AVDL10-QUrl
2023-05-041012477AVDL10-QUrl
2023-03-291012477AVDL10-KUrl
2022-11-091012477AVDL10-QUrl
2022-08-091012477AVDL10-QUrl
2022-05-091012477AVDL10-QUrl
2022-03-161012477AVDL10-KUrl
2021-11-081012477AVDL10-QUrl
2021-08-091012477AVDL10-QUrl
2021-05-101012477AVDL10-QUrl
2021-03-091012477AVDL10-KUrl
2020-11-091012477AVDL10-QUrl
2020-08-101012477AVDL10-QUrl
2020-05-111012477AVDL10-QUrl
2020-03-161012477AVDL10-KUrl
2019-11-121012477AVDL10-QUrl
2019-08-091012477AVDL10-QUrl
2019-05-081012477AVDL10-QUrl
2019-03-151012477AVDL10-KUrl
2018-11-051012477AVDL10-QUrl
2018-08-071012477AVDL10-QUrl
2018-05-041012477AVDL10-QUrl
2018-03-161012477AVDL10-KUrl
2017-11-091012477AVDL10-QUrl
2017-08-091012477AVDL10-QUrl
2017-05-101012477AVDL10-QUrl
2017-03-281012477AVDL10-KUrl
2016-11-141012477AVDL10-QUrl
2016-08-151012477AVDL10-QUrl
2016-05-101012477AVDL10-QUrl
2016-03-151012477AVDL10-KUrl
2015-12-311012477AVDL6-KUrl
2015-12-231012477AVDL6-KUrl
2015-11-231012477AVDL6-KUrl
2015-11-191012477AVDL6-KUrl
2015-10-131012477AVDL6-KUrl
2015-07-221012477AVDL6-KUrl
2015-07-101012477AVDL6-KUrl
2015-04-301012477AVDL20-FUrl
2014-11-171012477AVDL6-KUrl
2014-11-121012477AVDL6-KUrl
2014-09-151012477AVDL6-KUrl
2014-08-081012477AVDL6-KUrl
2014-08-041012477AVDL6-KUrl
2014-07-081012477AVDL6-KUrl
2014-07-021012477AVDL6-KUrl
2014-06-041012477AVDL6-KUrl
2014-05-211012477AVDL6-KUrl
2014-05-061012477AVDL6-KUrl
2014-04-301012477AVDL20-FUrl
2014-04-101012477AVDL6-KUrl
2014-03-111012477AVDL6-KUrl
2014-03-061012477AVDL6-KUrl
2014-02-141012477AVDL6-KUrl
2014-01-311012477AVDL6-KUrl
2014-01-151012477AVDL6-KUrl
2013-12-101012477AVDL6-KUrl
2013-12-061012477AVDL6-KUrl
2013-11-081012477AVDL6-KUrl
2013-09-191012477AVDL6-KUrl
2013-08-021012477AVDL6-KUrl
2013-07-151012477AVDL6-KUrl
2013-06-071012477AVDL6-KUrl
2013-05-281012477AVDL6-KUrl
2013-05-281012477AVDL6-KUrl
2013-05-161012477AVDL6-KUrl
2013-04-301012477AVDL20-FUrl
2013-04-021012477AVDL6-KUrl
2013-03-011012477AVDL6-KUrl
2013-02-121012477AVDL6-KUrl
2012-12-141012477AVDL6-KUrl
2012-12-041012477AVDL6-KUrl
2012-10-191012477AVDL6-KUrl
2012-09-131012477AVDL6-KUrl
2012-07-271012477AVDL6-KUrl
2012-06-261012477AVDL6-KUrl
2012-05-241012477AVDL6-KUrl
2012-05-071012477AVDL6-KUrl
2012-04-271012477AVDL20-FUrl
2012-03-211012477AVDL6-KUrl
2012-03-151012477AVDL6-KUrl
2011-12-231012477AVDL6-KUrl
2011-11-231012477AVDL6-KUrl
2011-11-021012477AVDL6-KUrl
2011-07-291012477AVDL6-KUrl
2011-07-251012477AVDL6-KUrl
2011-06-271012477AVDL6-KUrl
2011-06-241012477AVDL6-KUrl
2011-06-101012477AVDL20-FUrl
2011-05-311012477AVDL6-KUrl
2011-05-091012477AVDL6-KUrl
2011-05-041012477AVDL6-KUrl
2011-04-291012477AVDL6-KUrl
2011-03-041012477AVDL6-KUrl
2011-01-211012477AVDL6-KUrl
2010-11-041012477AVDL6-KUrl
2010-10-191012477AVDL6-KUrl
2010-10-131012477AVDL6-KUrl
2010-07-281012477AVDL6-KUrl
2010-06-251012477AVDL6-KUrl
2010-06-181012477AVDL6-KUrl
2010-05-271012477AVDL6-KUrl
2010-05-101012477AVDL20-FUrl
2010-05-051012477AVDL6-KUrl
2010-03-081012477AVDL6-KUrl
2010-01-151012477AVDL6-KUrl
2009-12-181012477AVDL6-KUrl
2009-11-161012477AVDL6-KUrl
2009-09-251012477AVDL6-KUrl
2009-08-061012477AVDL6-KUrl
2009-07-131012477AVDL6-KUrl
2009-06-251012477AVDL6-KUrl
2009-06-221012477AVDL6-KUrl
2009-06-121012477AVDL6-KUrl
2009-05-271012477AVDL6-KUrl
2009-05-191012477AVDL20-FUrl
2009-05-111012477AVDL6-KUrl
2009-03-201012477AVDL6-KUrl
2009-03-041012477AVDL6-KUrl
2009-02-231012477AVDL6-KUrl
2009-02-181012477AVDL6-KUrl
2009-01-091012477AVDL6-KUrl
2008-12-221012477AVDL6-KUrl
2008-11-031012477AVDL6-KUrl
2008-09-181012477AVDL6-KUrl
2008-09-181012477AVDL6-KUrl
2008-08-061012477AVDL6-KUrl
2008-06-181012477AVDL6-KUrl
2008-06-031012477AVDL6-KUrl
2008-05-141012477AVDL6-KUrl
2008-05-071012477AVDL20-FUrl
2008-05-071012477AVDL6-KUrl
2008-03-031012477AVDL6-KUrl
2008-01-081012477AVDL6-KUrl
2007-12-201012477AVDL6-KUrl
2007-10-311012477AVDL6-KUrl
2007-10-251012477AVDL6-KUrl
2007-10-191012477AVDL6-KUrl
2007-09-041012477AVDL6-KUrl
2007-08-021012477AVDL6-KUrl
2007-05-311012477AVDL6-KUrl
2007-05-231012477AVDL6-KUrl
2007-05-141012477AVDL6-KUrl
2007-04-301012477AVDL20-FUrl
2007-04-201012477AVDL6-KUrl
2007-03-141012477AVDL6-KUrl
2006-12-071012477AVDL6-KUrl
2006-11-061012477AVDL6-KUrl
2006-10-271012477AVDL6-KUrl
2006-08-111012477AVDL6-KUrl
2006-06-141012477AVDL6-KUrl
2006-06-141012477AVDL6-KUrl
2006-05-301012477AVDL6-KUrl
2006-05-231012477AVDL20-FUrl
2006-05-221012477AVDL6-KUrl
2006-05-161012477AVDL6-KUrl
2006-03-081012477AVDL6-KUrl
2006-01-111012477AVDL6-KUrl
2005-12-301012477AVDL6-KUrl
2005-11-231012477AVDL6-KUrl
2005-10-061012477AVDL6-KUrl
2005-09-091012477AVDL6-KUrl
2005-07-291012477AVDL6-KUrl
2005-07-251012477AVDL6-KUrl
2005-06-221012477AVDL6-KUrl
2005-06-151012477AVDL20-FUrl
2005-06-141012477AVDL6-KUrl
2005-06-141012477AVDL6-KUrl
2005-06-101012477AVDL6-KUrl
2005-06-081012477AVDL6-KUrl
2005-06-011012477AVDL6-KUrl
2005-05-241012477AVDL6-KUrl
2005-05-201012477AVDL6-KUrl
2005-05-061012477AVDL6-KUrl
2005-03-141012477AVDL6-KUrl
2005-03-041012477AVDL6-KUrl
2005-02-241012477AVDL6-KUrl
2004-09-011012477AVDL6-KUrl
2004-06-161012477AVDL6-KUrl
2004-05-281012477AVDL6-KUrl
2004-04-261012477AVDL20-FUrl
2003-12-311012477AVDL6-KUrl
2003-10-281012477AVDL6-KUrl
2003-09-171012477AVDL6-KUrl
2003-08-151012477AVDL6-KUrl
2003-07-151012477AVDL6-KUrl
2003-05-091012477AVDL6-KUrl
2003-04-251012477AVDL20-FUrl
2003-04-021012477AVDL6-KUrl
2002-10-251012477AVDL6-KUrl
2002-09-201012477AVDL6-KUrl
2002-08-091012477AVDL6-KUrl
2002-06-051012477AVDL20-FUrl
2002-05-091012477AVDL6-KUrl
2002-02-211012477AVDL6-KUrl
2002-01-291012477AVDL6-KUrl

Avadel Pharmaceuticals plc
(NASDAQ:AVDL) 

AVDL stock logo

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. T...

Founded: 1990
Full Time Employees: 50
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic

Share this website to your friends
The information provided in this report about AVDL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.